세계 양전자 방출 단층촬영(PET) 시장 규모는 2023년 17억 달러에서 2031년 25억 8,000만 달러에 달할 것으로 예상되며, 예측 기간인 2024-2031년 동안 연평균 5.1% 성장할 것으로 예상됩니다. 시장은 심장병, 뇌졸중, 암과 같은 만성 질환의 증가에 영향을 받고 있습니다. 이러한 만성 질환의 급증은 정확성과 조기 발견 능력으로 유명한 PET 스캔과 같은 첨단 진단 도구에 대한 수요를 증가시키고 있습니다. 또 다른 중요한 촉진요인으로는 해상도 향상 및 고속 스캔 능력과 같은 기술 발전이 있는데, 이는 복잡한 시술에서도 정확한 영상 촬영이 가능해져 궁극적으로 진단 정확도와 환자 예후를 개선할 수 있게 합니다. 또한, 하이브리드 PET/CT 및 PET/MRI 시스템의 도입은 임상 현장에서 PET 스캔의 효능을 다양화하고 강화하여 시장 성장을 촉진하고 있습니다.
정부의 노력과 자금 지원은 광범위한 연구개발(R&D), 인프라 확충, 상환 정책을 통해 세계 양전자 방출 단층촬영(PET) 시장을 주도하고 있습니다. 이러한 노력은 산업 내 투자 및 파트너십의 증가와 함께 기술 혁신을 촉진하고 PET 기술의 진화를 촉진하고 있습니다. 또한, 노인 인구의 급격한 증가로 인해 노화 관련 질병이 유행하면서 PET 검사에 대한 수요가 증가하고 있으며, PET 영상에 대한 인식과 수용도가 높아지면서 신경학, 순환기학 등의 분야로 확대되면서 진단 도구로서의 중요한 역할을 더욱 공고히 하고 있습니다.
확대되는 PET 스캔의 응용
양전자 방출 단층촬영(PET) 이미징의 적용 범위 확대는 시장 확대의 큰 원동력이 되고 있습니다. PET 이미징은 초기에는 종양 진단에서 그 우수성을 인정받았지만, 현재는 신경학, 순환기학 등 다양한 의료 분야로 확대되고 있으며, PET 기술의 발전과 새로운 방사성 추적자의 개발로 PET의 유용성은 계속 확대되고 있으며, 의료진은 질병 메커니즘, 치료 반응, 개별화 의료 접근법을 더 깊이 파고들 수 있습니다. 이러한 응용 분야의 증가는 환자 치료 수준을 향상시킬 뿐만 아니라 PET 영상 시스템에 대한 수요를 증가시켜 세계 PET 시장의 보급과 지속적인 성장에 크게 기여하고 있습니다. 또한, 장비의 민감도를 극대화하여 용량을 줄이고 더 빠른 진단을 제공할 수 있기 때문에 의료 분야 전반에 걸쳐 PET 스캔의 적용이 확대될 것입니다.
연구시설 설립
새로운 연구 시설의 설립은 세계 양전자 방출 단층촬영(PET) 시장의 주요 촉진요인입니다. 이러한 센터는 기술 혁신의 거점 역할을 하며 최첨단 PET 이미징 기술, 방사성 추적자 및 방법론의 발전을 촉진하는 역할을 하고 있습니다. 이들 센터는 공동 연구를 촉진하고 다양한 의료 응용 연구를 지원하며, 다양한 질환의 진단 및 추적에 있어 PET의 효능을 향상시키는 데 도움을 주고 있습니다. 이러한 노력은 투자와 공동 연구를 유치할 뿐만 아니라 PET 기술 개발을 촉진하고 의료에 대한 영향력을 증가시킵니다. 이 과정은 시장 확장을 촉진하고 진단 능력의 지속적인 발전을 보장합니다.
예를 들어, 2023년 12월 12일 호주 국립 전신 PET 시설(Australian National Total Body PET Facility)이 설립되었습니다. 이 시설은 암 연구, 신경 질환, 심혈관 질환 연구, 의약품 개발 등의 발전을 촉진할 것입니다. 이 시설의 도입은 스캔 시간과 방출선 피폭을 최소화하고 환자 치료의 기준을 혁신하는 것을 목표로 합니다.
정부의 노력
세계 각국 정부는 세계 양전자 방출 단층촬영(PET) 시장의 발전을 촉진하기 위한 전략을 적극적으로 시행하고 있습니다. 이러한 전략에는 연구 자금 지원, 기술 발전 촉진, PET 기술의 가용성 향상 등이 포함됩니다. 정부는 연구 개발을 지원함으로써 PET 이미징의 진화를 촉진하고 첨단 이미징 시스템 및 혁신적인 방사성 추적자 개발을 육성하고 있습니다. 또한, 의료 인프라를 개선하기 위한 노력과 상환 정책은 PET 스캔의 채택을 촉진하는 데 큰 역할을 하고 있습니다. 이러한 정부의 광범위한 노력은 PET 시장을 강화하고 그 확장을 촉진하며 현대 진단 의학에서 PET의 필수적인 역할을 강화하는 것을 목표로 합니다.
이 보고서는 세계 양전자 방출 단층촬영(PET) 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 현황 및 전망 등의 정보를 전해드립니다.
Global positron emission tomography market is projected to witness a CAGR of 5.1% during the forecast period 2024-2031, growing from USD 1.7 billion in 2023 to USD 2.58 billion in 2031. The global positron emission tomography market is being influenced by the increasing prevalence of chronic diseases such as heart diseases, stroke, and cancer. This surge in chronic diseases is increasing the demand for advanced diagnostic tools like PET scans, known for their precision and early detection capabilities. Another important driver include technological advancements, such as increased resolution and fast scanning abilities, which enable precise imaging for complicated procedures, ultimately enhancing diagnostic precision and patient outcomes. Moreover, the introduction of hybrid PET/CT and PET/MRI systems have diversified and enhanced the effectiveness of PET scans in clinical settings, thereby propelling the growth of global positron emission tomography market.
Government initiatives and funding are also driving the global positron emission tomography market through extensive research and development (R&D), expansion in infrastructure, and reimbursement policies. Combined with increased investments and partnerships within the industry, these efforts encourage innovation and propel PET technology's evolution. Additionally, a burgeoning elderly population is increasing the demand for PET scans as age-related ailments become more prevalent. Growing recognition and acceptance of PET imaging, along with its expansion into fields like neurology and cardiology, is further solidifying its pivotal role as a diagnostic tool.
Growing Application of PET Scans
The growing scope of positron emission tomography (PET) imaging applications significantly drives the market expansion. Initially recognized for its dominance in oncology diagnostics, PET imaging now spans diverse medical domains like neurology and cardiology. With the evolution of PET technology and the development of novel radiotracers, its utility continues to grow, empowering healthcare experts to delve deeper into disease mechanisms, treatment responses, and personalized medical approaches. This increased array of applications not only elevates patient care standards, but also increases the demand for PET imaging systems, thus significantly contributing to the widespread adoption and continuous growth of the global positron emission tomography market. In addition, the device's maximized sensitivity can be used to reduce the dosage and offer faster diagnosis, which will expand the application of PET scans across the healthcare domain.
Establishment of Research Facilities
The establishment of new research facilities is a key driving factor for the global positron emission tomography market. These centers act as innovation hubs, nurturing the advancement of cutting-edge PET imaging technologies, radiotracers, and methods. They facilitate joint research endeavors, support the exploration of various medical applications, and help improve PET's effectiveness in diagnosing and tracking different conditions. These initiatives not only draw investments and collaborations, but also expedite the development of PET technology, amplifying its influence on healthcare. This process stimulates market expansion and guarantees ongoing progress in diagnostic capabilities.
For example, the establishment of The Australian National Total Body PET Facility occurred on December 12th, 2023. Marking Australia's inaugural total body PET scanner available for unrestricted research use, this facility is poised to propel progress in cancer research, neurological disorders, cardiovascular disease studies, and pharmaceutical development. Its implementation aims to minimize scanning durations and radiation exposure, thereby revolutionizing patient care standards.
Government Initiatives
Governments around the globe are proactively implementing strategies to drive the advancement of the global positron emission tomography market. These strategies involve financing research, promoting technological progress, and improving the availability of PET technology. By supporting R&D, governments encourage the evolution of PET imaging, nurturing the development of advanced imaging systems and innovative radiotracers. Moreover, initiatives to improve reimbursement policies and healthcare infrastructure play a major role in driving the adoption of PET scan. These extensive government initiatives aim to strengthen the PET market, fostering its expansion and reinforcing its essential role in contemporary diagnostic medicine.
For instance, in November 2023, as a part of the Chief Minister's Comprehensive Health Insurance Scheme, Coimbatore Medical College Hospital (CMCH) received a boost with the commissioning of a PET CT (Positron emission tomography and computed tomography) scan machine worth INR 12 crore. At the CMCH, the procedure, which would have cost INR 20,000 in private hospitals, would only cost INR 6,500 to INR 11,000, with the Chief Minister's insurance plan covering the cost.
Increasing Use of PET Scan in Oncology
The use of PET in oncology is significantly driving the global market. PET imaging's accuracy in identifying and tracking cancerous developments supports early detection, precise staging, and evaluation of treatment response. Its capacity to offer comprehensive metabolic insights into tumors aids oncologists in making informed decisions. As PET technology advances persistently and new radiotracers emerge, its role in oncology is also growing. This progression not only enhances patient results, but also substantially bolsters the global adoption and growth of PET technology.
For instance, Meilleur Technologies, Inc. unveiled a research collaboration pact with the Young Blood Institute (YBI) on exploring the application of Meilleur's [F-18]NAV-4694, an investigative imaging agent, in positron emission tomography examinations. This device is designed to evaluate the presence of amyloid plaque within the brain. Amyloid plaques signify a prominent feature across various neurodegenerative conditions, notably Alzheimer's disease.
Advanced Software Solutions in Positron Emission Tomography
The increasing demand for PET software solutions is acting as a driving force behind the expansion of the global positron emission tomography market. With healthcare institutions progressively depending on PET imaging for precise disease diagnosis and monitoring treatments, there's a growing requirement for advanced software that improves image processing, analysis, and interpretation. Advanced PET software enhances workflow efficiency, facilitates precise data analysis, and improves the integration of PET scans with other imaging methods. This increased demand not only enhances the effectiveness of PET technology, but also contributes to market growth by meeting the changing demands of healthcare practitioners to deliver enhanced patient care.
For example, in May 2023, Precision DL (GE HealthCare), an AI-driven image processing software, received 510(k) clearance from the Food and Drug Administration (FDA). This software is anticipated to deliver notable enhancements in contrast-to-noise ratio (CNR), precision in quantifying features, and the ability to diagnose small lesions in PET scans.
Future Market Scenario (2024-2031F)
The future of the global positron emission tomography market exhibits remarkable promise, poised for substantial expansion. Various factors are contributing to this positive projection. Advancements in PET technology, encompassing enhanced imaging resolution, faster scan speeds, and the creation of novel radiotracers are expanding PET scan applications with increased accuracy. Furthermore, the surge in chronic diseases worldwide, alongside a growing elderly population, is increasing the demand for precise diagnostic tools like PET scans. Additionally, PET's diversified usage spanning beyond oncology into segments like neurology, cardiology, and psychiatric disorders solidifies its significance in healthcare diagnostics. Collaborative endeavors between public and private sectors, reinforced by supportive government measures and improved reimbursement policies, foster market growth. Besides this, ongoing research and technological advancements are expected to position the global positron emission tomography market for notable progress and evolution in the coming years.
Key Players Landscape and Outlook
Key global positron emission tomography market players are establishing strategic alliances. These partnerships among leading firms seek to combine resources, knowledge, and technologies, aiming to propel advancements in PET imaging. These collaborations focus on stimulating innovation, creating state-of-the-art PET systems, and pioneering new radiotracers. Such affiliations enable the integration of diverse strengths, fostering research and expediting the introduction of advanced PET solutions. Ultimately, these initiatives are driving the market's progression, ensuring refined diagnostic accuracy and substantially contributing to PET technology's global growth and progression.
In September 2023, Jubilant DraxImage Inc., operating as Jubilant Radiopharma, a wholly owned subsidiary of Jubilant Pharma Limited, initiated an exclusive collaboration with Cardiac Imaging, Inc. in Oakbrook Terrace, Illinois. The partnership aims to offer healthcare facilities a daily-leased rubidium solution for conducting cardiac PET scans, thereby enhancing access to cutting-edge cardiac PET imaging for patients suspected of coronary artery disease (CAD).
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work